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Several causes have been considered in the etiology of 
CVT. These factors including all causes of deep vein 
thrombosis in the legs, genetic, malignancy, prothrombin 
related disorders, deficiency of folic acid and vitamin 
B12, and hyperhomocysteinemia (hyper-Hcys).[3,4]
Hyper-Hcys or rising of homocysteine in blood has been 
related to smoking, old age, renal and liver diseases, 
and vitamins deficiency as well as genetic disorders 
affecting the remethylation pathway of homocysteine 
metabolism. High level of total homocysteine results 
from interaction of genetic and related determinants. 
Moreover, deficiencies of folic acid and vitamin B12 are 
the other causes of hyper-Hcys.[5] In fact, lowering effect 
of vitamin B12 and folic acid on homocysteine has been 
seen in clinical trials.[6,7]
INTRODUCTION
Cerebral vascular thrombosis (CVT), a type of 
cerebrovascular disease, is the thrombosis of intracranial 
and sinuses.[1] For the first time, CVT was recognized 
at the early nineteenth century and that time thought 
CVT was infective disease resulting in seizures and 
bilateral or other focal abnormalities.[2] Today, CVT is 
recognized as a noninfective disorder accompanied by 
various clinical symptoms and mortality less than 10%.[2] 
The approved diagnostic methods for CVT are magnetic 
resonance imaging (MRI) and magnetic resonance 
angiography.[3] In addition, heparin is the first line of 
treatment. Because of wide spectrum and symptoms and 
cases, diagnosis of CVT is still overlooked and delayed.[3] 
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The association of high levels of homocysteine with vascular 
damages such as thrombosis, atherosclerosis, and some 
ischemic diseases as well as other neurological disease such 
as migraine has been found in several investigations.[8,9] 
Hyper-Hcys has been considered as a risk factor for CVT 
in several studies.[10,11] However, no clear information is 
available for relation between hyper-Hcys and related 
vitamins deficiency with CVT in Iranian patients.
Some evidences have evaluated the association of CVT 
with vitamin B12 and folic acid deficiency as well as 
hyper-Hcys.[12,13] Vitamin supplementation with folic 
acid and cobalamin lowers the plasma levels of tHcy in 
most cases.[6,7] Thus, hyper-Hcys as a risk factor for CVT 
may relate to folic acid and vitamin B12 deficiency. To 
the our knowledge, there is no local study investigating 
nutritional deficiency of vitamin B12 and folic acid with 
CVT in northwest Iran. We conducted this study to compare 
vitamin B12 and folic acid deficiency prevalence between 
CVT patients and healthy subjects and to evaluate the 
relationship of hyper-Hcys, low vitamin B12, and low folic 
acid with the risk of CVT occurring in northwest Iran.
MATERIALS AND METHODS
Study design and participants
A total of 24 patients with CVT and 36 healthy controls 
participated in a cross-sectional case-control study from 
May 2010 to March 2012. The patients with definite 
diagnosis of CVT referred to Emam Reza Hospital of Tabriz 
were invited to take part in the study. CVT was diagnosed 
by computed tomography (CT) or MRI. The patients with 
conditions that influenced homocysteine concentration, such 
as renal or thyroid disease, or who were in anticonvulsant 
therapy with phenytoin or carbamazepine were excluded 
from study. The control participants were chosen from 
partners with no cancer, liver disease, renal failure, and 
surgery who agreed to take part in study matched for age 
(±5 years) with the patients with cerebral vein thrombosis. 
They were recruited at the same time as cases. The case 
subjects ranged from 14 to 61 years old (mean = 32.2, SD 
= 10.8) who were in two gender (men; N = 4, women; N = 
20). The control participants (men; N = 9, women; N = 27) 
ranged from 14 to 61 years old (mean = 33.04, SD = 11.6). The 
presence of circumstantial thrombosis risk factors, such as 
oral contraceptive drugs intake, pregnancy, cancer, surgery, 
and trauma, were reported for both patients and controls. 
This study was approved by Ethics Committee of the Tabriz 
University of Medical Sciences. All of the participants were 
informed about the design of the study and were assured 
about data confidentiality, safeness of the study, and the 
voluntary nature of their participation. All the participants 
provided written informed consent. 
Procedures and variables assessment
Blood sampling was done at the breakfast and after 
overnight fasting and the samples were stored at –80°C until 
analyzed. Serum total homocysteine concentrations were 
determined on frozen samples by high-performance liquid 
chromatography (HPLC) method (KNAUER, Germany), 
coupled with fluorescence detector.[14] For evaluating folic 
acid and vitamin B12, the samples were collected in tubes 
protected from light and levels of folate and vitamin B12 
were measured simultaneously in the frozen serum aliquot 
by a double labeled radioassay kit (ICN Pharmaceuticals, 
New York) (Stat Fax 4200, Awareness Technology, USA) in 
all cases and controls.
Statistical analysis
Statistical analysis was conducted using SPSS 15 for 
Windows (SPSS, Chicago, IL). Variables were tested for 
normal distribution using the Kolmogorov–Smirnov test. 
For normally distributed continuous variables, mean and 
standard deviation were calculated, and for nonnormally 
distributed variables, median and range were used. The 
χ2 test was used for categorical variables. Mann–Whitney 
U-test was used for comparing homocysteine level between 
groups because data were not normally distributed. In the 
patient’s group, vitamin B12 levels in two samples were 
observed as outlier. Therefore, the final analysis was done 
on 22 participants in the case group. We used independent 
t-test for comparing serum levels of folic acid and vitamin 
B12 between the case and control groups. The deficient level 
of folic acid and vitamin B12 defined as <10th percentile of the 
control group.[12] Similarly, hyper-Hcys was defined as >90th 
percentile of homocysteine level of the control group.[12] We 
used crude odds ratio (OR) and 95% confidence interval (CI 
95%) with by simple cross-tabulation for estimating the risk 
of hyper-Hcy, vitamin B12, and folate deficiency for CVT. 
Adjusted OR for CVT was obtained by multiple logistic 
regression analysis. The significance level was established 
at a value of P = 0.05. 
RESULTS
General characteristics and clinical outcomes
The baseline descriptive characteristics of patients and 
controls are shown in Table 1. There was no significant 
difference in age between patients and controls. Four 
patients (16.7%) and 12 controls (33/3%) were male and no 
significant gender proportion difference was found between 
groups. The most common symptoms of patients were 
headache (83.3%), focal symptoms (41.7%), seizure (33.3%), 
and nausea and vomiting (29.6%). Results of imaging 
showed that the sagittal sinuses in 13 patients (54.2%) and 
lateral sinuses in 8 patients (33.3%) are the most typically 
involved sinuses. 
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Levels of tHcys, vitamin B12, and folic acid and related 
correlation
The 90th percentile for tHcys was 10.2 µmol/L and 10th 
percentile for folic acid and B12 levels in the control 
group were 211.9 ng/mL and 11.69 ng/mL, respectively. 
These values were defined as cutoff levels for hyper-
Hcys, low folic acid, and low vitamin B12. Although 
patients had higher levels of tHcys (14.7 ± 6.5 vs. 6.4 ± 
2.7 µmol/l, P = 0.001) and lower levels of vitamin B12 
(185.4 ± 58 vs. 299 ± 75 ng/ml, P = 0.001) than controls, 
folic acid did not differ between groups. Hyper-Hcys 
and low vitamin B12 were significantly more prevalent 
in CVT patients than that in controls (70.7% vs. 7.9%, 
P = 0.001; 58.3% vs. 2.6%, P = 0.001) [Table 2]. Although 
a significant negative correlation was found between 
levels of tHcys and vitamin B12 (r = -0.32, P = 0.01), no 
significant association was observed between tHcys and 
folic acid neither between vitamin B12 and folic acid 
levels (data were not shown).
Risk assessment
Crude and adjusted ORs are presented in Table 2. 
Adjusted OR was estimated by adjusting each variable for 
the others. After adjusting for low vitamin B12 and low 
folic acid, hyper-Hcys showed significant independent 
association with risk of CVT (adjusted OR 13.5, 95% 
CI: 2.5-72.5, P = 0.002). In addition, low vitamin B12 
remained a potent risk factor for CVT after adjusting 
for low folic acid and hyper-Hcys (adjusted OR 3.2, 95% 
CI:1.8-34.5, P = 0.015).
DISCUSSION
Although studies have reported that hyper-Hcys is an 
important risk factor for CVT, there are rare evidence 
in Iranian CVT patients. In our study, we evaluated 
homocysteine and related vitamins in the CVT patients 
and compared with controls. Our study showed that 
CVT patients had higher levels of homocysteine and 
lower level of B12 compared to controls. There was no 
significant difference in folic acid between case and control 
groups. In agreement to our study, a study by Martinella 
et al.[15] showed that the CVT patients had higher level of 
homocysteine than the controls, but the levels of B12 and 
folic acid did not differ between the groups. In line with our 
results, a study conducted in Indian CVT subjects revealed 
a higher level of homocysteine, lower level of folic acid, and 
B12 compared to control volunteers.[13] Similarly, another 
study carried out among Mexican CVT patients showed 
higher level of Hcys and lower level of folic acid in the CVT 
group than controls.[12] The small sample size as a potent 
limitation in our study as a potent limitation and various 
dietary pattern as well as different value of animal protein 
intake, as a main source of vitamin B12 and folic acid in 
diet, may be explanations for disparity between studies.
A significant reverse correlation was revealed between 
B12 levels and tHcys. But this correlation was not found 
between folic acid level and tHcys. In contrast, Nageraja 
et al. reported significant correlation between tHcys and folic 
acid levels in the CVT patients but not between tHcys and 
vitamin B12 levels.[13] Similar results were found in other 
studies conducted in CVT and coronary artery disease.[16,17] 
In other study, Abdulle et al. found that total plasma 
homocysteine concentration had an inverse correlation 
with both vitamin B12 and folate.[18] In agreement with our 
study, the results of study conducted in Iranian population 
showed significant negative correlation between vitamin 
B12 and homocysteine concentration.[19] It is implied that 
in our study subjects, deficiency of vitamin B12 may be a 
cause for the increase in fasting Hcys.
Since 1998, the fortification of cereal grain flour products with 
folic acid was mandated in the United States. Supplementation 
Table 2: Risk estimation of hyperhomocysteinemia, low vitamin B12, and low folic acid for CVT
Variablea Patients 
(N = 22)
Controls 
(N = 36)
Crude OR 
(95% CI)
P Adjusted ORc 
(95% CI)
P
Hyper-Hcys (>10.2 µmol/L) 15 (68.2) 3 (7.9) 28.3 (6.5-123.1) 0.001 14.3 (2.6-77.1) 0.002
Non-hyper-Hcys (≤10.2 µmol/L)b 7 (31.8) 33 (92.1) 1 1
Low vitamin B12 (<211.9 ng/mL) 14 (62.7) 1 (2.6) 51.1 (6.1-442.6) 0.001 24.6 (2.3-262.9) 0.008
High vitamin B12 (≤211.9 ng/mL)b 8 (36.3) 35 (97.4) 1 1
Low folic acid (<11.69 ng/mL) 6 (27.2) 3 (7.9) 3.5 (0.4-31.9) 0.056 3.5 (0.4-31.9) 0.25
High folic acid (≤11.69 ng/mL)b 16 (72.8) 33 (92.1) 1 1
Hyper-Hcys = Hyperhomocysteinemia; a Values expressed as N (%); b Considered as reference group in logistic regression analysis; c Hyper-Hcy was adjusted for low vitamin B12 
and folate. Low vitamin B12 and folate were adjusted for each other and for hyper-Hcy
Table 1: Baseline characteristics and laboratory findings 
of the study
Variablea Patients 
(N = 22)
Controls 
(N = 36)
P
Age (years) 32.2±10.8 35.3±11.9 0.3b
Gender: N (%) 0.07c
Male 4 (16.7) 12 (33.3)
Female 20 (83.3) 24 (63.2)
Plasma Hcysd (µmol/L) 15 (3.9-27.4) 5.95 (1-14.3) 0.001e
Plasma vitamin B12 (ng/mL) 185.4±58 299±75 0.001b
Plasma folic acid (ng/mL) 16.5±9.4 14.8±2.6 0.4b
aValues expressed as mean ± SD; bIndependent t-test. cχ2 test; dValues expressed as 
median (range); eMann–Whitney U-test
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with folate resulted in about 20-25% reduction in tHcy 
levels and cerebrovascular diseases in the United States. The 
government of Iran passed a law in 2005 to require wheat 
flour fortification, and the law was implemented nationwide 
by 2007. In northwest Iran, the Tabriz Registry of Congenital 
Anomalies reported a NTD rate of 16.9 per 10,000 live births 
in 2005 which dropped to 7.0 per 10,000 in 2006.[19] 
To the our knowledge, this study is a first evaluation of 
folic acid and B12 levels in the patients with cerebral vein 
thrombosis in northwest Iran after flour fortification with 
folic acid program. Results of our study indicate that folic 
acid fortification may cover folic acid deficiency as a risk 
factor for hyper-Hcys. 
It seems that folic acid fortification program among Iranian 
population may lead to increase of folic acid intake and no 
significant association between folic acid and tHcys was 
found in CVT patients.
Findings of our study suggested that Hyper-hcys may be a 
potent risk factor for CVT patients. In our study, the OR for 
CVT in people with hyper-Hcys was 14.3 after adjusting for 
low vitamin B12 and folic acid levels. The study by Nagarja 
et al.[13]  showed that adjusted OR for puerperal CVT in 
patients with hyper-Hcys was 10.8 (95% CI, 4.0-29.4; P < 0.001). 
Similarly, Cantu et al.[12] found an OR of 3.9 for CVT in subjects 
with hyper-Hcys. In consistent, the case control study by 
Martinelli et al.[15] found hyper-Hcys in 33 of 121 patients (27%) 
and 20 of 242 healthy controls (8%; OR, 4.2; 95% CI, 2.3 to 7.5). 
Our study found that low vitamin B12 not low folic acid had 
a significant independent association with the risk of CVT. 
This suggests that risk of CVT is mediated through hyper-
Hcys and vitamin B12 deficiency. The study by Cantu et al. in 
Mexican people found that hyper-Hcys as well as low level 
of folic acid and vitamin B12 had independent association 
with the risk of CVT, suggesting mechanisms other than 
hyper-Hcys should be considered for the risk of CVT. 
Our study is a case control study and therefore it has some 
limitations. Confounding variables were not eliminated and 
controls were chosen from the same source of cases. Level of 
tHcys is dependent on renal function. Although we did not 
measure creatinine levels, subjects were selected from the 
people reporting no renal disease. In our study, because of 
sample size limitation we found wide rages of CI compared to 
other studies. In addition, we did not record a history of diet.
CONCLUSION
In conclusion, our findings are in agreement with the 
hypothesis that hyper-Hcys is associated with the increased 
risk of CVT. Furthermore, low vitamin B12 level was related 
significantly with high risk for CVT, but folic acid level was 
not associated directly with risk of CVT. Further, long-time 
studies with large sample size are needed to assess the 
mechanism and effect of hyper-Hcys, low vitamin B12, and 
low folic acid on the risk of CVT.
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